ECRONICON OPEN ACCESS

EC CANCER
Research Article

Correlation Between Methylenetetrahfolate Reductase (MTHFR) C677T Polymorphism, Fluoropyrimidines Response And Toxicity In Patients Treated For Locally Advanced Rectal Cancer

K Boudaoud[1]*, S Taleb[1], T Filali[2], H Boudaoud[3], K Sifi[4], A Brihmat[4] and N Abadi[4]

[1]*Department of radiation therapy, University Constantine, Algeria*

[2]*Department of medical oncology, University Constantine, Algeria*

[3]*Department of general surgery, Batna University, Algeria*

[4]*Scientific research laboratory of molecular biology and genetics, University Constantine, Algeria*

***Corresponding Author:** K Boudaoud, Department of radiation therapy, University Constantine, Algeria.

Received: February 25, 2016; **Published:** April 01, 2016

Abstract

Background: Preoperative radiation therapy combined with fluoropyrimidines is the standard treatment for locally advanced rectal cancer. However, there is a large individual difference or variation in tolerability and therapeutic efficacy due to polymorphisms in genes encoding drug metabolizing enzymes, drug transporters, and/or drug targets (e.g., receptors, enzymes). The genetic polymorphisms represent one of the major causes in this variation. The aim of our study is to analyze the relationship between Methylenetetrahydrofolate Reductase "MTHFR" (important enzyme in Fluoropyrimidines metabolism) gene polymorphism, tolerability and the therapeutic efficacy of Fluoropyrimidines in patients with locally advanced rectal cancer.

Materials and Methods: DNA extraction was performed on 52-blood samples collected between December 2011 and November 2013 were analyzed for; MTHFR gene polymorphism was determined by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) in patients with stage II and III histologically proved rectal cancer. There were 21 women and 31 men with a median age 50.8 years, range 23-70 years. The tumor was located in the lower rectum in 55.7% of cases. 30 patients had stage III rectal cancer. Preoperative radiation therapy was delivered in all patients with a total dose of 45 Gy, combined with fluoropyrimidine (5Fluorouracil + folic acid in 30 patients, Capecitabine in 22 patients), followed by surgical resection within eight weeks in all patients. The treatment tolerability was evaluated according to the NCI-CTC version 3 toxicity criteria. Therapeutic efficacy was evaluated by histopathological postoperative specimen examination. Kaplan-Meyer survival curves were defined for each polymorphism in our series.

Results: The distribution of the three genotypes CC, CT and TT were respectively (48%, 32.6%, and 19.2%). The risk of developing severe (grade 3-4) toxicity was observed in 677CC (28%), 677CT (35%) and 677TT (20%). T-level down staging and complete response after neoadjuvant treatment were demonstrated in 60% of cases in patients with 677TT genotype, 56% in 677CT genotype and 58.8% in 677CC genotype. No association was observed between C677T polymorphism and survival (log rank = 0.02, p = 0.99).

Conclusion: In spite of the limited patient number (52 patients), our study shows that the MTHFR 677 TT genotype can have a protective role for fluoropyrimidine toxicity, and it can be a predictive factor in therapeutic efficacy. This study will be continued, in order to include more patients.

Keywords: *Helicobacter pylori; Intrafamilial transmission and Childhood*

Introduction

Combined preoperative fluoropyrimidines (5Fluorouracil, Capecitabine) and radiation therapy is the standard treatment for locally advanced rectal cancer. Pathologic downstaging (DS) or a pathologic complete response (pCR) after preoperative chemoradiation has been correlated with improved survival, decreased recurrence and a higher rate of sphincter-preserving surgeries [1-7]. However, there is a large individual difference or variation in tolerability and therapeutic efficacy. The genetic polymorphisms represent one of the major causes in this variation [1,8-10]. Factors that cause variations in drug response are multifold and complex. At molecular level, genetic variability of drug metabolizing enzymes has long been recognized as a factor in therapeutic response and drug toxicity [11-13]. Identifying pharmacogenomics factors in drug tolerability and response would develop treatment tailored to each patient [14-17]. Several studies have investigated the impact of genetic polymorphism in enzymes involved in folate and fluoropyrimidines metabolism. Thymidylate synthase (TS), the target enzyme of 5-fluorouracil (5-FU), dihydropyrimidine dehydrogenase (DPD), the main player of 5-FU catabolism in the liver and methylenetetrahydrofolate reductase (MTHFR), directly linked to the TS reaction. Two polymorphisms of MTHFR have been reported to determine enzyme activity: MTHFR-C677T and MTHFR-A1298C. The aim of our study is to analyze the relationship between gene polymorphism C677T of the methylenetetrahydrofolate Reductase "MTHFR", tolerability and the therapeutic efficacy of fluoropyrimidines in patients with locally advanced rectal cancer. We attempted also to study its impact on the sphincter preservation rate, pelvic local control, survival and established a DNA bank.

Patients and Methods

Eligibility Criteria

The study was conducted between December 2011 and November 2013. Population consisted of patients with histologically documented rectal adenocarcinoma. The patients that were eligible to participate in this study, were 18 to 70 years old, had tumor extension through the bowel wall (T3-T4) or pelvic lymph-node involvement (according to the TNM classification 7th edition 2009) [18] and lower pole of the primary tumor was less than 15 cm from anal verge margin (as determined by clinical work-ups, including computed tomography, pelvic magnetic resonance imaging and/or endoscopic ultrasound), with a good performance status OMS (PS = 0 or 1). However those with history of malignancy treated with pelvic radiotherapy, or prior chemotherapy, synchronous metastases, and patients rescued from surgery (for other serious medical condition), were not included in this study. Patients who fulfilled the above eligibility criteria were made aware of the study aim and were required to sign the informed consent.

Genetic Study

Blood samples (6 to 10 ml) were collected on Ethylene Diamine Tetraacetic Acid Tube (EDTA) for DNA isolation and determination of genotypes. The presence of MTHFR mutations was determined by isolation of genomic DNA from peripheral lymphocytes and amplification of the target sequence by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP).

Treatment

All patients received preoperative concurrent pelvic radiation therapy associated with fluoropyrimidines. The total irradiation dose of 45 Gy was delivered using conventional fractionation (daily fractions of 1.8 Gy/five days per week over 5 weeks). Concurrent fluoropyrimidines were administered as 5 Fluorouracil (750mg/m2, day 1-5 in IVI/22 hours) combined with folic acid (20 mg/m^2/d over 30 minutes), in two cycles; the first cycle was administered during days 1 to 5 of the external-beam radiotherapy and the second cycle was administered on days 29 to 33. In some patients treatment was administered as capecitabine continuously throughout the 5 weeks of radiotherapy course at 825 mg/m2 given twice daily 5 days per week during the days when radiotherapy was delivered. Surgery was planned approximately 6-8 weeks after the complétion of chemoradiotherapy.

Treatment Evaluation

We assessed patients by clinical and hematological examination weekly during treatment. Toxicities were evaluated using the National Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTC v 3.0) [19]. Therapeutic efficacy was evaluated by histopathological postoperative specimen examination according to the pTNM staging system. A tumor and/or nodal downstaging

was considered when pathological T (pT) and/or pathological N (pN) was lower than clinical T and/or N as defined by computed tomography and/or magnetic resonance imaging obtained after preoperative concurrent chemoradiation. Evaluation of histological regression was carried out according to rectal cancer regression grading established by Wheeler and al [20] grade 1, sterilization or only microscopic foci of adenocarcinoma remaining with marked fibrosis; grade 2, marked fibrosis but macroscopic disease; and grade 3, little or no fibrosis with abundant macrocopic disease. Kaplan-Meyer survival curves were defined for each polymorphism. Relationships between MTHFR C677T polymorphism variants and the incidence of grade 3–4 toxicity, tumor response (measured by DS and ypT0 rates) and overall survival were assessed. Overall survival was calculated in weeks between the start of treatment and death of 50% of patients. The SPSS software package (version 22.0J; SPSS Inc.; Chicago, IL, USA) was used for statistical analyses.

Results and Discussion

Patients and Tumors Characteristics

Between December 2011 and November 2013 a total of 52 patients, 31 men and 21 women, with locally advanced rectal adenocarcinoma were enrolled in this study. Patient characteristics are summarized in Table 1. The median age was 50.8 years (ranging from 23-70 years). Family history of cancer was found in 5 cases (four colorectal cancer and one breast cancer). Average time between first symptoms and diagnosis was 7.4 months (1- 24 months). Tumor was located in the lower rectum in 29 cases (55.7%); 58% of the patients (30 pts) had stage III rectal cancer.

Patients and tumor characteristics	**N of patients (N = 52)**
Median age, years	50.8 (23-70)
Gender	
Men	31
Women	21
Pathological history	
Family history of cancer	05
Familial adenomatous polyposis	02
Diabetes	03
High blood pressure	03
Average time: first symptom - diagnosis (month)	**7.4 months (1- 24 months)**
Clinical symptoms	
Rectal bleeding	35
Change in bowel habits	15
Mucous discharge	09
Pain	04
Tumor site	
Low rectum	29
Mid rectum	23
TNM clinical stage	
T3N0M0 : stage II	22
T3N1M0 : stage III	27
T3N2M0 : stage III	1
T4N1M0 : stage III	1
T4N2M0 : stage III	1

Chemotherapy	
5Fluorouracil+ Folic Acid	30
Capecitabine	22

Table 1: *Patients and tumor characteristics.*

Genotyping of MTHFR C677T

The genotyping results are presented in Table 2. Twenty-five patients (48%) had homozygous normal or CC genotype. 17 patients were heterozygous (CT) and 10 individuals (19, 2%) were homozygous for the mutation (TT).

MTHFR 677 C >T Genotype	N of patients	Percentage (%)
CC	25	48
CT	17	32.6
TT	10	19.2

Table 2: *MTHFR genotypes distribution.*

In the prospective French study published in the British Journal of Clinical Pharmacology (BJCP) to evaluate the predictive value of gene polymorphism potentially related to 5FU and oxaliplatin pharmacodynamics in advanced colorectal cancer treated with FOLFOX (enrolled 117 patients), MTHFR genotypes distribution (CC, CT and TT) was shown respectively in 44, 58 and 14 cases (37.6%, 49, 5% and 11.9%) [21]. In the American study published in 2011, concerning MTHFR gene polymorphism and 5FU toxicity combined with preoperative concurrent radiotherapy in 131 patients with locally advanced rectal cancer [22], MTHFR genotypes (CC, CT and TT) was found in 60, 59 and 12 cases respectively (45.8%, 45.03% and 9.16%). The TT genotype frequency observed in Salvatore Terrazzino et al study included 125 patients with rectal adenocarcinoma treated with concurrent preoperative chemoradiation therapy using 5FU was lower: 677CC (n = 41, 33%), 677CT (n = 57, 46%) and 677TT (n = 27, 22%) [23].

Impact of C677T Polymorphism and Fluoropyrimidines Toxicity

Tolerability was satisfactory, with grade 3-4 toxicity observed in 13.4% of patients for diarrhea and 15.3% for radiation dermatitis. 677 (CC–CT) genotypes were related to a higher rate of grade 3–4 toxic events respectively (35%, 28%). Grade 3-4 diarrhea was found in 4CC genotype and 2CT genotype respectively (16% and 11.7%), 8 patients presented grade 3-4 radiation dermatitis (3CC, 4CT et 1TT), only 2 patients with 677TT have grade 3-4 toxicity (20%).

MTHFR 677 C >T Genotype	Leukopenia G3-4	Diarrhea G3-4	Radiation dermatitis G3-4	%
CC	0	4	3	28
CT	0	2	4	35
TT	0	1	1	20

Table 3: *C677T polymorphism and fluoropyrimidines toxicity.*

677TT genotype seems to have a protective role in the toxicity of grade 3 and 4 (Figure 1). In our study, patients with CT MTHFR genotype have an increased risk of developing severe acute toxicity due to fluoropyrimidines treatment. The TT genotype of the MTHFR C677T polymorphism was protective against grade 3-4 toxicity.



Figure 1: *C677T polymorphism and Fluoropyrimidines toxicity.*

In Etienne-Grimalkins., *et al.* study published in the British Journal of Clinical Pharmacology [21], grade 3 and 4 toxicity occurred in 22.9% of cases. None of the analyzed gene polymorphisms were predictive of toxicity considered either as the maximum observed grade, or as the toxicity score. The study of S. Afzal *et al.* showed that grade 3-4 toxicity was overrepresented among patients with genotype CC 677 with an odds ratio (OR) confidence interval [95% (CI) ; 1.13 - 2.96, p = 0.01] 1.83 [24].

Impact of C677T Polymorphism and Treatment Response

After completion of concurrent chemoradiation and before surgery, evaluation of response was defined clinically. Tumor response was assessed by computerized tomography and/or magnetic resonance imaging. Down staging was achieved in 4/10 patients with 677TT (40%) (Table 4). Pathological complete response (pCR; ypT0N0M0) was observed in two cases (20%) (Table 5). In those with 677CT and 677CC, down staging and histological sterilization were obtained respectively in 6CT, 1CT (35.2%, 5.8%) and 13CC, 1CC (52%, 4%). Down-staging and histological sterilization of the surgical specimen were obtained respectively in 23 patients (44.2%) and 4 patients (7.6%). The best overall response was obtained in 677TT (60%) (DS in 40%, histological sterilization in 20%).

Sohn and al [8] demonstrated on human cancer cells, a very high sensitivity to 5FU in the genotype 677T relative to 677C. In clinical trials, the impact of MTHFR gene polymorphism in tolerability and therapeutic efficacy is still controversial. Cohen et al. [25] were the first to describe a link between C677T MTHFR gene polymorphism and tumor response to 5FU-based chemotherapy. In this study conducted on 43 patients with metastatic colorectal cancer, therapeutic response was achieved in all patients with 677TT (5 patients), it was 50% in patients with 677CC. In a retrospective study from Etienne and al including 98 colorectal cancer patients with liver metastases receiving FUFOL, responsiveness was significantly linked to 677C→T genotype, with an increased response rate in 677TT tumors relative to 677CC (odds ratio = 1.88) [26]. In contrast, a study by Marcuello and al failed to show a link between MTHFR polymorphisms and clinical response in 94 metastatic colorectal cancer patients receiving FU associated with irinotecan or oxaliplatin [27]. In Terrazzino Salvatore et al study, the aim was to evaluate the impact of MTHFR gene polymorphism on tumor regression, in 125 patients treated with concurrent preoperative radiation therapy associated at 5FU. Tumor regression was frequent in patients with genotype 677CC (57%) compared to genotype 677CT and 677TT, which were respectively (27% and 37%) [23].

TNM	N patients	ypTNM	N patients (ypTNM)	N patients (stage)
T3N0M0 = stage II	22	T0N0M0	4	4 = stage 0
T3N1M0 = stage III	27	T1N0M0	9	
T3N2M0 = stage III	1	T2N0M0	7	15 = stage I
T4N1M0 = stage III	1			
T4N2M0 = stage III	1	T2N1M0	1	
		T3N0M0	18	1 = stage III
		T3N1M0	12	18 = stage II
		T4N1M0	1	12 = stage III
		T4N2M0	1	1 = stage III
				1 = stage III
Stage II : 22				Stage 0: 4
Stage III : 30				Stage I: 15
				Stage II:18
				Stage III:15

Table 4: *ypTNM classification.*

MTHFR C677T genotype	N patients	Downstaging (DS)	Complete response (pCR)
CC	25	13	1
CT	17	06	1
TT	10	04	2

Table 5: *Impact of MTHFR gene polymorphism C667T on response.*

All patients underwent curative surgical resection. 30 patients (57.7%) underwent low anterior resection (sphincter-preserving surgery). 22 patients (42%) patients underwent abdominal-perineal resection in low rectal tumor (distance from the lower pole of the primary tumor to the anal verge was less than 4 cm). In 29 tumors localized in low rectum, 7 patients underwent low anterior resection (n = 4; 677CC, n = 2:677CT and n = 1; 677TT).

MTHFR C677T genotype	Anterior resection	Abdominal-perineal resection
CC	14	05
CT	11	10
TT	05	07
	30	22

Table 5: *Impact of MTHFR gene polymorphism C667T on sphincter-preserving surgery.*

Impact of C677T Polymorphism on Survival

The overall survival of all patients has been followed up every 3 months for the first 2 years after the end of treatment. Overall survival at 2 years was 88% (Figure 2). In this study overall survival was not significantly different among patients with 677 (TT, CT, and CC) genotypes; this was respectively (88.9%, 88.2%, 87.5%; p = 0.9) (Figure 3). Clinical studies on genetic variation investigating the impact of MTHFR C677T polymorphism in colorectal cancer treated with 5FU on survival rate have mainly focused on patients undergoing treatment for metastatic disease and 5FU- based adjuvant chemotherapy. Most of the reported studies were conducted in a small number of patients (less than 150) and have shown varying results with almost equal numbers showing no effect, a positive effect, or a negative effect on survival, response.



Figure 2: *Overall survival.*



Figure 3: *Impact of C677T polymorphism on survival.*

Conclusion

In spite of the limited patient number, our study shows that the MTHFR 677 TT genotype can have a protective role on fluoropyrimidine toxicity, and it can be a predictive factor in therapeutic efficacy. This study will be continued, in order to include more patients and to analyze the second polymorphism in MTHFR gene (1298 A > C). Due to the encouraging results of this limited study, further patient follow-up and study analysis is warranted.

Bibliography

1. Molinari C., *et al.* "Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer". *Clinical Colorectal Cancer* 14.4 (2015): 227-238.
2. De Caluwe L., *et al.* "Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer". Cochrane Database of Systematic Reviews 2 (2013).
3. Sauer R., *et al.* "Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years". *Journal of Clinical Oncology* 30.16 (2012): 1926-1933.
4. Bujko K., *et al.* "Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer". *British Journal of Surgery* 93.10 (2006): 1215-1223.
5. Sauer R., *et al.* "Preoperative versus postoperative chemoradiotherapy for rectal cancer". *The New England Journal of Medicine* 351.17 (2004): 1731-40.
6. Sebag-Montefiore D., *et al.* "Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial". *Lancet* 373.9666 (2009): 811-820.
7. Ortholan C., *et al.* "Oxaliplatin and preoperative chemoradiotherapy in rectal cancer". *Bull Cancer* 93.S1 (2006): S51-S8.
8. Sohn KJ., *et al.* "Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate". *Journal of the National Cancer Institute* 96.2 (2004): 134-144.
9. Yamayoshi Y., *et al.* "Cancer pharmacogenomics: international trends". *International Journal of Clinical Oncology* 10.1 (2005): 5-13.
10. Derwinger K., *et al.* "A study of the MTHFR gene polymorphism C677T in colorectal cancer". *Clinical Colorectal Cancer* 8.1 (2009): 43-48.
11. Ceppa F., *et al.* "Role of pharmacogenetics in chemotherapy of colorectal cancers". *Revue de Médecine Interne* 28.9 (2007): 594-602.
12. Stohlmacher J. "Pharmacogenetics in gastrointestinal tumors". *Onkologie* 28(8-9) (2005): 435-440.
13. Sekine I and N Saijo. "Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents". *Annals of Oncology* 12.11 (2001): 1515-1525.
14. Burnat P., *et al.* "Pharmacogénétique des anticancéreux". *Médecine et Armées* 31 (2003): 490-494.
15. Bourel M and R Ardaillou. "Pharmacogenetics and pharmacogenomics". *Bull Acad Natl Med* 190.1 (2006): 9-22.
16. Lotz P and D Brault. "Complications biologiques des traitements médicaux des cancers". *Feuill Biol* 2.252 (2003): 59-62.
17. Robert J. "Pharmacogénétique et pharmacogénomie". *Bull Cancer* 93 (2006): 113-123.
18. Sobin LH., *et al.* "TNM classification of malignant tumours". *Wiley-Blackwell* (2010): 310.
19. Program CTE. "Common Terminology Criteria for Adverse Events (CTCAE)". (2006).
20. Wheeler JM., *et al.* "Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system". *Diseases of the Colon & Rectum* 45.8 (2002): 1051-1056.
21. Etienne-Grimaldi MC., *et al.* "Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients". *British Journal of Clinical Pharmacology* 69.1 (2010): 58-66.
22. Thomas F., *et al.* "Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer". *British Journal of Cancer* 105.11 (2011): 1654-62.

23. Terrazzino S., *et al.* "A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation". *Pharmacogenetics and Genomics* 16.11 (2006): 817-824.
24. Afzal S., *et al.* "MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer". *Annals of Oncology* 20.10 (2009): 1660-1666.
25. Cohen V., *et al.* "Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy". *Clinical Cancer Research* 9.5 (2003): 1611-1615.
26. Etienne MC., *et al.* "Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity". *British Journal of Cancer* 90.2 (2004): 526-534.
27. Marcuello E., *et al.* "Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?" *Cancer Chemotherapy and Pharmacology* 57.6 (2006): 835-840.

Volume 2 Issue 2 March 2016